XXII 22nd Century Group Inc.

22nd Century Group (XXII) Launching VLN® at #1 U.S. C-Store Chain in Texas, California and Florida

22nd Century Group (XXII) Launching VLN® at #1 U.S. C-Store Chain in Texas, California and Florida

Largest U.S. C-Store Chain Will Add VLN® to More Than 1,450 Corporate Stores in Three Largest State Markets, Incentivizes Additional 3,100 Franchise Stores to Join the Launch

Full Support from Corporate and Franchise Owners Association to Commence VLN® Sales in Franchise Locations

BUFFALO, N.Y., June 06, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced that its VLN® reduced nicotine content cigarettes will be sold in the #1 convenience store (C-Store) chain in the U.S. at more than 1,450 corporate locations in Texas, California and Florida. An additional 3,100 franchise owned stores in these state markets are incentivized to add VLN® products with full support from corporate and the national franchise owners organization. Franchise owned stores are already submitting product orders.

The launch will utilize 22nd Century Group’s new national and regional distribution agreements, including agreements with both the #1 and #2 C-store distributors in the United States. Stocking orders to distributors will commence in late-June, with corporate stores and the first wave of franchise stores expected to begin selling VLN® products in early July.

“Adding the country’s #1 C-store chain and launching the three largest state markets will significantly and quickly expand the availability of VLN® to thousands of additional stores,” stated John Miller, president of tobacco products for 22nd Century Group. “Franchise stores are already confirming orders to add VLN® in conjunction with the corporate rollout, which will include media outreach, in-store offers, signage and a range of education and awareness tools across a variety of channels designed to drive adult smokers to VLN®.”

Mr. Miller continued, “In addition to rapidly adding corporate and franchise owned stores in these new markets, we are also scheduling launches with other new regional c-store, pharmacy and military chains, plus regional and state business units of existing chains, that will further expand VLN®’s availability in multiple markets. These launch plans give us increased visibility into additional stores and states through the rest of the year, keeping us on track to reach our stated growth goals.”

Industry surveys indicate that 75% of smokers want to quit, and a majority of smokers try to quit each year, yet only a small percentage are successful. For smokers who are ready, VLN® reduced nicotine content cigarettes have been shown to decrease consumption, decrease dependence and reduce toxicants, providing a much-needed tool for millions of adult smokers to reduce their reliance on nicotine and smoke less.

“We are excited to deliver on our commitment to launch with major C-store retailers and new national-scale distribution resources as we work to rapidly expand sales of our VLN® products in up to 18 states by the end of 2023,” said James A. Mish, chief executive officer of 22nd Century Group. “VLN® sales are accelerating as planned, keeping us on track to achieve cash positive operations in our tobacco business in 2024.”

Market Data and Additional VLN® Background

22nd Century’s distribution agreements with the #1 and #2 U.S. C-Store products distributors, plus a growing list of regional distribution, provide solutions for convenience stores, mass merchants and drug stores seeking to carry the Company’s revolutionary VLN® reduced nicotine content cigarettes.

Combined, Texas, California and Florida represent more than 1.7 billion packs per year of cigarettes smoked, , generating retail sales in excess of $14.4 billion.

  • Approximately 15% of Texans smoke, making it the largest cigarette market in the United States. Texas smokers consume an estimated 736 million packs per year, resulting in $5.6 billion in annual retail sales.
  • Approximately 10% of Californians smoke, consuming an estimated 514 million packs per year, resulting in $4.9 billion in retail sales.
  • Approximately 15% of Floridians smoke, consuming an estimated 513 million packs per year, resulting in $3.9 billion in retail sales.

22nd Century Group's VLN® brand cigarettes are the first and only combustible cigarettes that the FDA has authorized as Modified Risk Tobacco Products (MRTP). The Company's VLN® King and VLN® Menthol King contain 95% less nicotine than traditional addictive cigarettes, a level considered to be minimally or non-addictive. Reduced nicotine content cigarettes, such as VLN®, have been studied extensively by federal health agencies, documenting their ability to help smokers smoke less. To inform adult smokers of the product's distinctive purpose, the FDA requires 22nd Century to include the statement "Helps You Smoke Less" on every package of VLN® sold.

As demonstrated by leading , reducing the nicotine level in cigarettes has the potential to substantially reduce the enormous burden of smoking-related death and disease. It is estimated that a nicotine product standard to a level that is 95% less than the level of nicotine contained in U.S. conventional cigarettes could save millions of lives and tens of millions of life-years over the next several decades.

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: ) is a leading biotechnology company focused on utilizing advanced alkaloid plant technologies to improve health and wellness through tobacco harm reduction, reduced nicotine tobacco, hemp/cannabis and hops. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the  to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. In tobacco, hemp/cannabis and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at , on , on , and on .

Learn more about VLN® at .

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 9, 2023. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact

Matt Kreps

Investor Relations

22nd Century Group



214-597-8200



EN
06/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 22nd Century Group Inc.

 PRESS RELEASE

Emerging Growth Research Releases Q2 2025 Update Report on 22nd Centur...

New York, New York--(Newsfile Corp. - August 22, 2025) - Emerging Growth Research today released its latest quarterly update report on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q2 2025 results. The report reflects ongoing operational restructuring under new management and revised outlook for EBITDA breakeven pushed to Q2 2026 due to slower-than-expected CMO stabilization and VLN® rollout timing.22nd Century Group Q2 2025 Financial Highlights:Q2 2025 revenue of $4.1 million, down 49% year-over-year from $7.9 million in Q2 2024Q2 2025 revenue declined 31% sequentially from...

 PRESS RELEASE

Emerging Growth Research Releases Q1 2025 Update Report on 22nd Centur...

New York, New York--(Newsfile Corp. - May 21, 2025) - Emerging Growth Research today released its latest quarterly update report on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q1 2025 results. The report reflects the continued operational progress made under new management and the outlook for meaningful financial improvement in 2025.22nd Century Group Q1 2025 Financial Highlights:Q1 2025 revenue of $6.0 million, up 48% from Q4 2024Q1 2025 gross profit improved to $(0.6) million from $(1.3) million in Q4 2024Operating loss narrowed significantly to $(2.6) million from $(4.4...

 PRESS RELEASE

Emerging Growth Research Releases Quarterly Update Report on 22nd Cent...

Sheridan, Wyoming--(Newsfile Corp. - April 10, 2025) - Emerging Growth Research is pleased to release its latest quarterly update on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q4 2024 results. The report reflects the continued operational progress made under new management and the outlook for meaningful financial improvement in 2025.To read the full report, please visit: Q4 2024 Financial Highlights:Revenue was $4.0 million, down 45% YoY, reflecting expected attrition due to CMO contract price hikes. Gross profit improved YoY to $(1.3) million from $(7.8) million. Opera...

 PRESS RELEASE

Emerging Growth Research Releases New Initiation Report on the 22nd Ce...

Sheridan, Wyoming--(Newsfile Corp. - February 19, 2025) - Emerging Growth Research is pleased to announce the release of its new initiation report on the 22nd Century Group, Inc. (NASDAQ: XXII). The Company has made significant strides in its operational and financial restructuring under new management, with only the warrant overhang remaining to be addressed. To read this report, please visit XXII's landing page on the Emerging Growth website, located here: .XXII's new management has successfully reduced operating cash losses in the first nine months of 2024 and further decreased the Company'...

 PRESS RELEASE

22nd Century Secures $3.2 Million to Date in Warrant Exchange Transact...

22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction Newly Appointed CEO Leading Restructuring to Focus on Tobacco Industry Operations, Reduce Costs BUFFALO, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the exercise of warrants by certain holders pursuant to its previously announced warrant inducement offering. During the inducement period, certain holders of the Company’s existing warrants acqui...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch